March 5, 2018 Price forecast | 2 weeks: -0.53% | 1 month: -1.77% | 3 months: -1.98%


MGNX stock forecast

Our latest prediction for MacroGenics, Inc.'s stock price was made on the March 5, 2018 when the stock price was at 31.00$.

In the short term (2weeks), MGNX's stock price should underperform the market by -0.53%. During that period the price should oscillate between -8.18% and +8.53%.

In the medium term (3months), MGNX's stock price should underperform the market by -1.98%. During that period the price should oscillate between -17.75% and +21.56%.

Create a solid portfolio with MGNX

Add MGNX to your portfolio and optimize it!


About MacroGenics, Inc.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

At the moment the company generates 68M USD in revenues.

On its last earning announcement, the company reported a loss of -3.08$ per share.

The book value per share is 7.39$

MacroGenics, Inc. website


Three months stock forecastMarch 5, 2018


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
68M - -175M -256.60% -152M -3.08 - - 49M 7.39 -148M -4M -152M